Resistance to thyroid hormone (RTH), with elevated serum free thyroid hormones and nonsuppressed thyrotropin levels, is either relatively asymptomatic, suggesting a generalized disorder (GRTH) Invest. 1994. 94:506-515.)
Introduction
The syndromes of resistance to thyroid hormone (RTH)1 are rare disorders characterized by reduced tissue responsiveness hTRP, thyroid hormone receptor /3; Ka, affinity constant; PRTH, pituitary resistance to thyroid hormone; RTH, resistance to thyroid hormone; TRE, thyroid response element; TSH, thyroid stimulating hormone.
to thyroid hormones (thyroxine [T4] and triiodothyronine [T3] ). The synthesis of these hormones is controlled by thyroid stimulating hormone (TSH) from the pituitary, and, in turn, they regulate TSH production as part of a negative feedback loop (1) . The hallmark of RTH is resistance to thyroid hormone action within the pituitary-thyroid axis, such that continued TSH production drives hypersecretion of T3 and T4 to establish a new equilibrium with high serum levels of free thyroid hormones together with a nonsuppressed TSH. Although this disorder exhibits marked phenotypic variability, two major forms have been described on the basis of clinical features. Many affected individuals are asymptomatic and clinically euthyroid, with characteristic abnormal thyroid function tests, leading to a diagnosis of generalized RTH (GRTH) (2) . In other cases, similar hormonal abnormalities are associated with a variety of thyrotoxic features, suggesting that peripheral tissues are less refractory to thyroid hormones than the pituitary, allowing a diagnosis of pituitary resistance (PRTH) to be made (3) . In addition, features such as growth retardation in children or hypercholesterolemia indicate that some tissue responses to thyroid hormone can be in the "hypothyroid" range (2) .
In humans, two homologous thyroid hormone receptors (hTRa and hTR,/) are encoded by separate genes on chromosomes 17 and 3, respectively. Alternative splicing of each gene generates three major receptor isoforms hTRa l, hTR/31, and hTRP2 with differential tissue expression. Thus hTRal and hTRf31 are ubiquitously expressed, whereas TR/32, which has been isolated in the rat and mouse, is most highly expressed in the pituitary and hypothalamus (4) . Current models suggest that thyroid hormone action is mediated by interaction of these receptors with specific DNA sequences or thyroid response elements (TREs) in the promoter region of target genes. For many target genes, the receptor binds as a heterodimer with the retinoid X receptor (RXR) (5), but homodimeric interactions have also been demonstrated in some cases (6) . The presence of ligand results in activation or repression of target gene transcription.
In 1988, familial GRTH was shown to be tightly linked to the TR3 gene locus (7) . Since then, 26 different hTR/3 gene mutations have been described in a large number of kindreds with this disorder (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . More recently, analyses of two unrelated cases of PRTH showed that they also harbored mutations in hTRP (25, 26) . An early report suggested that the mutations clustered within two regions in the hormone-binding domain of the receptor (11) , and a subsequent series has confirmed this observation (22) . Consistent with their location, functional studies indicate that the mutant receptors exhibit moderately or markedly impaired ligand-binding properties (27) (28) (29) . In addition, they are able to inhibit the action of wild-type receptor when coexpressed (27, 28) . This dominant negative inhibitory activity varies depending on the nature of the mutation (29) , as well as the configuration of TRE (30, 31 ). Evidence in favor of the dominant negative effect of mutant receptors in vivo is provided by the observation that individuals who are heterozygous for a complete deletion of one hTR,3 allele are normal (12) , whereas an individual who was homozygous for a dominant negative receptor mutation showed severe resistance (32) .
In 
Methods
Hormone assays. In a single case (T.B.) serum free T4 (FT4) was measured by an SPAC FF4-fraction assay (Byk-Sangtec Diagnostica, Dietzenbach, The Netherlands). All other hormone measurements in Table II were carried out with the same assay methodology. Serum FI4 and free T3 (FT3) levels were measured with fluoroimmunometric assays using Delfia technology (Wallac, Milton Keynes, UK). TSH measurements used a sensitive "second generation" assay method (Delfia; Wallac). The intra-and interassay coefficients of variation were < 10% throughout.
DNA extraction and sequence analysis. Blood samples were obtained from members of each kindred, and leukocyte DNA was extracted using standard techniques. For each index case, exons 4-10 of the hTR/3 gene were amplified using PCR with flanking intronic oligonucleotide primers. Primer sequences are shown in Table I . In each case the antisense primer was 5 '-biotinylated to allow single-stranded DNA template to be generated before sequencing. PCR was performed using 1 sg of genomic DNA and 10 pmol of each primer in a 50-/ul reaction volume containing 10 mM Tris-HCl (pH 8.3), 50 mM KC1, 2 mM MgCl2, 0.01% gelatin, 500 pM dNTPs, and 0.5 U of Taq polymerase (PerkinElmer Cetus, Norwalk, CT). The reaction conditions were denaturation at 94°C for 3 min, then annealing at 55°C for 30 s, followed by 30 cycles of extension at 72°C (30 s), denaturation at 94°C (30 s) , and annealing at 60°C (30 s). The PCR product was captured using streptavidin-coated magnetic beads (DYNABEADS M-280 streptavidin; DY-NAL, Wirral, UK) and then was denatured with 0.2 M NaOH to remove the nonbiotinylated sense strand. The immobilized biotinylated antisense strand was then sequenced directly using an internal intronic primer (Table I) was amplified from genomic DNA using PCR and digested with the appropriate enzyme, and the product was analyzed by agarose gel electrophoresis. All PCR primers and reaction conditions were as originally described (33) . T3 binding assays. Mutations were recreated by site-directed mutagenesis of the hTRfll cDNA in Ml3mpl8 as described previously (15) and confirmed by sequencing of individual phage plaques. Mutant receptor cDNAs were subcloned into pGEM 7z to generate receptor protein by coupled in vitro transcription and translation with rabbit reticulocyte lysate (TNT; Promega, Southampton, UK). The T3 binding affinity of each mutant receptor was determined using a filter binding assay. In vitro translated receptor (2-4 pl) was incubated for 1 h at 30°C in 500 il binding buffer (20 mM Tris-HCl, 50 mM KCl, 1 mM MgCl2, 1 mM dithiothreitol, pH 8.0) containing 0.01 nM '251-T3 (sp act 3,000 1iCi/ ,ug) and unlabeled competitor ligand. Bound ligand was separated from free by filtering through Millipore HAWPO2500 filters (Millipore Corp., Bedford, MA). Scatchard analysis was performed to generate affinity constants (Ka), and the results shown are the mean of three or more separate determinations. In some cases, specific T3 binding was detectable but was too low to be quantified by Scatchard analysis; in these, Ka is indicated as < 0.02 x 10'0 M-1. BND indicates cases where no specific T3 binding was detected (Table II) . Table III . Three individuals (propositus, mother, and sister) showed elevated serum Ff4 levels but, interestingly, corresponding FIT3 concentrations were elevated to varying levels on some occasions but normal at other times. In the father, serum FIT4 and FIT3 levels were well within the normal range. In kindred M.P., the index case was initially noted to have an elevated serum total T4 concentration (175 nmol/liter, normal 75-145 nmol/liter) and TSH level (7. 7 mU/ liter). The suspicion of a pituitary tumor on CT scan was not (Table II) . 20 different mutations were identified, comprising 13 novel and 7 previously described mutations. 19 are single nucleotide substitutions resulting in a codon change in the predicted protein sequence (Fig. 1 A) . In one case, a duplication of seven nucleotides causes a shift in reading frame and the addition of four codons at the carboxyl terminus of the receptor, together with alteration of some residues between codons 452 and 461 (Fig. 1 B) . With one exception, all these mutations localize to exons 9 and 10, corresponding to two regions within the hormone-binding domain which have contained the majority of mutations reported to date (2) . In a single case (G.P.), a mutation in exon 8 leads to a valine to aspartic acid substitution at codon 264 (V264D) which is located in the hinge region of the receptor.
Having identified a mutation in the index case, all other available first-degree relatives within each kindred were analyzed for this defect by direct sequence analysis. 
Discussion
The cardinal feature of resistance to thyroid hormone is an impairment of feedback regulation within the pituitary-thyroid axis, manifested by elevated serum free thyroid hormone concentrations, together with a nonsuppressed TSH level. We have described 29 kindreds exhibiting these biochemical abnormalities and identified 20 different mutations in the TRB gene in affected individuals, occurring sporadically or in a dominantly inherited manner. On this background, the clinical manifestations were widely variable, with the absence or presence of thyrotoxic features leading to a diagnosis of GRTH or PRTH, respectively. In males with the X-linked androgen insensitivity syndrome, deleterious mutations have been described throughout the androgen receptor (39) , while recessively inherited vitamin Dresistant rickets is characterized by DNA-binding domain mutations in the majority of cases (40, 41) . By contrast, dominantly inherited RTH is associated with receptor mutations which cluster within the hormone-binding domain, and our analyses confirm this observation with the location of 28 mutations conforming to the two "hot spot" regions described previously (11, 22) . However, novel mutations within our series expand the boundaries of each hot spot region which now extend from codons 310 to 349 and 429 to 461. In addition, we have identi- fied a single mutation (V264D) which localizes to the hinge (D) domain of the receptor, outside the two major mutation clusters and representing only the second such example described (16) . The ability of the mutant proteins to bind ligand is moderately or severely impaired (Table II) . Other studies have shown that mutant receptors retain the ability to bind to DNA (27) (28) (29) either as homodimers (42) or heterodimers with the retinoid X receptor (30) . These functional properties correlate with the observation that RTH mutations lie outside the DNA-binding domain and highly conserved motifs (43) (44) (45) that are known to be involved in dimerization. We and others (27, 28) have also shown that the mutant receptor proteins inhibitwild-type receptor action in a dominant negative manner. Importantly, this inhibition has been observed with reporter genes containing not only positive TREs (29) (30) (31) , but also the human TSHa promoter (15, 28, 46) , which is negatively regulated by hTR/3. A number of models have been proposed to account for dominant negative inhibition (28, 42) , but recent studies indicate that artificial mutations that abolish DNA binding or heterodimerization with RXR are able to abrogate dominant negative inhibitory effects with reporter genes containing the hTSHa promoter or positive TREs (47, 48) . These observations suggest that receptor mutations which impair ligand-dependent transcriptional function, yet retain DNA binding and dimerization potential, are associated with RTH. In particular, (11) K443E (20) fs448 (1 1) L450H (19) P453H (9) fs454 (22) F459C ( we suggest that the ability to exert a dominant negative effect within the pituitary-thyroid axis is a key property of mutant proteins and generates the characteristic biochemical abnormality that leads to the detection of the disorder. As a corollary, it is tempting to speculate that mutations elsewhere in the receptor that are also transcriptionally impaired elude discovery because they lack dominant negative activity and are therefore biochemically and clinically silent. However, such structure-function correlations might not be the sole determinants of the clustered distribution of receptor mutations in RTH. Our data also indicate that within these two major clusters, mutations are nonuniformly distributed, such that some codon changes are particularly frequent. Weiss et al. (24) reported that six RTH mutations occurring in more than one kindred were all either transitions in CpG dinucleotides or occurred in GC-rich regions (defined as 2 4 consecutive Gs or Cs). In our series also (Table IV) (Table IV) agrees with these proportions, with CpG transitions constituting the majority (83%) of recurrent and a minority (6%) of unique mutations. CpG dinucleotides are frequent sites of point mutation in several other genes (e.g., Factor IX); this probably results from deamination of 5'methyl-cytosine (thought to occur preferentially in CpG motifs) to thymidine, converting CG to TG or CA (49, 50) . We therefore suggest that, where a mutation-prone CpG dinucleotide concurs with a cluster, certain codon changes are overrepresented (e.g., R338W X10, R438H X7, A317T x5).
Although we have observed complete concordance between resistance in the pituitary-thyroid axis and a TRB gene defect, individual patients exhibited widely variable serum levels of FT4, FT3, and TSH, which did not correlate with the nature of the mutation or the ligand-binding properties of mutant receptor proteins. We have shown recently that the biological activity of TSH is variably elevated in patients with RTH (51) and suggest that this might, in part, account for the variations in serum free thyroid hormone levels. Kindred deG. showed mildly elevated thyroid hormone concentrations with temporal variations such that, in some instances, either FT4 or FT3 levels (but never both) were within the normal range. All biochemically affected individuals in this family harbored an arginine to histidine mutation in codon 316 of hTR,6. In a separate kindred, the same mutation was associated with biochemical resistance in one patient but normal thyroid function tests in two other members (23) . The authors correlated these observations with the lack of dominant negative activity of this mutant receptor on a positive TRE-containing reporter gene and suggested the possibility of a second genetic defect to account for resistance in their index case.:We have found that the R316H receptor mutant does exert a dominant negative effect, particularly when tested using the negatively regulated hTSHa gene promoter (data not shown). To reconcile these differences, we suggest that this mutation can engender mild resistance in the pituitary-thyroid axis, but that the severity of this impaired feedback can be modulated by other factors. This may account for the association of the R316H mutation with mild RTH in our kindred but normal thyroid function in another family. In this context, a recent study (52) , which showed normal but above average FT4 levels in unaffected members of a kindred with RTH, supports the notion that other non-receptor-related processes can influence the biochemical phenotype.
Earlier studies had not described a clear mode of inheritance in PRTH, leading to the suggestion that it might represent a different pathophysiologic entity (2) Lastly, the possibility of other novel, nonreceptor mechanisms by which TR signaling could be disrupted to produce RTH should be considered. The occurrence of sporadic hTR/3 mutations in a number of families, as well as identical mutations in unrelated kindreds, suggests that de novo mutations account for a proportion of RTH cases and that the disorder might be more common than appreciated hitherto. The widespread availability of FI4 and sensitive TSH assays allows the biochemical detection of RTH and this can now be combined with screening exons 7-10 in hTR/3 using the robust, automated direct sequencing techniques we have described to make a definitive diagnosis. In GRTH, early recognition of the disorder is beneficial in preventing inappropriate thyroid ablative treatment, and in PRTH the judicious lowering of thyroid hormone levels may help to alleviate thyrotoxic symptoms. The combined use of hormone assay and genetic technologies will facilitate the screening of neonates or selected groups to determine both the prevalence of this condition and its phenotypic and genetic spectrum.
